Tourette study with Gemlapodect
Dr. Chris Van der Linden is leading an international study into Gemlapodect, a new treatment for Tourette syndrome. This innovative therapy restores dopamine balance in the brain to reduce motor and vocal tics. The research is ongoing at BRAI3N in collaboration with Noema Pharma (Switzerland).
Description
Tourette study with Gemlapodect
This international, double-blind and placebo-controlled Phase IIB study studies the effects and safety of Gemlapodect in adolescents and adults with Tourette syndrome (TS).
Gemlapodect is a novel, selective PDE10A inhibitor that acts on brain circuits involved in tic regulation. The substance aims to reduce motor and vocal tics by balancing dopamine signals in the brain.
A total of approximately 140 patients are participating in this study.
The treatment lasts 12 weeks, followed by a follow-up period of 4 weeks.
Efficacy is assessed using standardized scales such as the Yale Global Tic Severity Scale (YGTSS-R), while closely monitoring safety, side effects, and quality of life.
BRAI3N is one of the participating centers in this international clinical trial, sponsored by Noema Pharma (Switzerland).
The research is led by Dr. Chris van der Linden
Contact about this project
Do you have questions about this research project or would you like to receive more information? Feel free to contact our team.
Other research projects
Ready to take the first step?
Our specialists are here to help you. Find out what treatments are possible or schedule a consultation.